Leif Johansson is being proposed as the next Non-Executive Chairman of the Board in AstraZeneca PLC (LSE: AZN, OMXS: AZN, NYSE: AZN). Johansson is currently the Chairman of Ericsson and from 1997 until 2011, he was Chief Executive of Volvo AB. His pharmaceutical industry experience is from a non-executive director position at Bristol-Myers Squibb from 1998 to September 2011. Swedish stakeholders might feel appeased by the suggestion after the latest personnel cuts have hit home hard. Current Chairman Louis Schweitzer, who is about to turn 70, intends to retire on September 1st 2012.
AstraZeneca also announced that it had received an approval from the FDA for intranasal four-strain influence vaccine FluMist Quadrivalent. This is the first FDA approval for a vaccine containing two type A strains and two type B lineages designed to protect against influenza A and B. AstraZeneca advanced mildly in Thursday trading.
No comments:
Post a Comment